East Rutherford, NJ – Cambrex Corporation (NYSE: CBM, “Cambrex”), a leading provider of products and services to the life sciences industry, is celebrating 30 years of service and operations. With production sites in the US, Europe and India, and sales throughout the world, Cambrex specializes in the development and manufacture of small molecule Active Pharmaceutical Ingredients (APIs) and intermediates to support the clinical and commercial needs of the pharmaceutical and biotechnology industries.
A History of Innovation, Experience and Performance
Founded in 1981 by Cyril C. Baldwin, Jr. and Arthur Mendolia, the Company began operations as CasChem, manufacturing specialty and fine chemicals for niche market segments. The Company changed its name to Cambrex Corporation in 1987.
In 1991, Cambrex entered the life sciences and pharmaceutical industries with the acquisition of Salsbury Chemicals, now Cambrex Charles City, specialists in the manufacture of intermediates and APIs for the pharmaceutical industry. Cambrex significantly expanded its operations internationally in 1994, with the acquisition of Nobel Chemicals AB in Karlskoga, Sweden, and Profarmaco S.r.l. in Milan, Italy, now Cambrex Karlskoga and Cambrex Profarmaco Milano, respectively, both leaders in the manufacture of generic and branded APIs and intermediates.
Cambrex continues to actively invest to strengthen its life sciences offerings. With the 2008 acquisition of Estonia-based Prosyntest, Cambrex added a group of world class R&D chemists to their already strong custom development group. In 2010, Cambrex acquired IEP GmbH in Wiesbaden, Germany, a leader in biocatalytic transformations, to broaden its existing enzymatic biocatalysis capabilities. Most recently, Cambrex acquired a 51% share in Zenara Pharma, a Hyderabad, India-based pharmaceutical company focused on final dosage form products and Nicotine Replacement Therapies (NRT).
“We are extremely proud to celebrate Cambrex’s 30 years of success and reputation as a world leader in providing products and services for small molecule therapeutics,” said Cambrex President and CEO, Steven M. Klosk, “Moving forward, we remain committed to meeting our customers’ needs for quality, reliability and innovation.”